Targeting the eicosanoid pathway in non-small-cell lung cancer

Author： Horn Leora   Backlund Michael   Johnson David H  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.13, Iss.6, 2009-06, pp. : 675-688

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Gefitinib in Non-Small-Cell Lung Cancer

By Frampton James E.   Easthope Stephanie E.  

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 133-136

Adis International

Access to resources Recommend Favorite

Vandetanib for the treatment of non-small-cell lung cancer

By Wong Hui-li   de Boer Richard H  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 14, 2011-10 ,pp. : 2271-2278

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for non-small-cell lung cancer

By Felip Enriqueta   Santarpia Mariacarmela   Rosell Rafael  

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 3, 2007-09 ,pp. : 449-460

Informa Healthcare

Access to resources Recommend Favorite

Axitinib for the treatment of advanced non-small-cell lung cancer

By King Judy W  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 6, 2013-09 ,pp. : 765-773

Informa Healthcare

Access to resources Recommend Favorite

Vandetanib has value in non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite